SCHEMBL3018558

SCHEMBL3018558

O=S(=O)(c1cc(C(F)(F)F)ccc1Cl)C1CCN(c2nc(-c3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.44
SMN1; SMN2 Q16637 8/20 0.43
ALDH1A1 P00352 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
RAB9A P51151 8/20 0.42
MAPK1 P28482 2/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
TSHR P16473 1/20 0.41
ATM Q13315 1/20 0.41
NPC1 O15118 7/20 0.40
MAPT P10636 4/20 0.40
LMNA P02545 1/20 0.40
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
FFAR2 O15552 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007024 0.96 AR (0.45) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3018473 0.95 AR (0.45) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3006719 0.92 SMN1; SMN2 (0.47) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3016913 0.92 AR (0.52) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3019160 0.90 SMN1; SMN2 (0.47) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3006658 0.89 SMN1; SMN2 (0.44) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3014737 0.89 SMN1; SMN2 (0.42) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3009295 0.89 AR (0.43) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3008837 0.89 SMN1; SMN2 (0.49) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL3009425 0.88 MEN1 (0.49) ARSMN1; SMN2ALDH1A1L3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.